Author

S. Perlman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 10 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 9 Organism:mouse· 6 Research Focus:drug response / drug discovery· 5 Organism:human· 2 Assay:proteomics· 2 Organism:virus· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

L. Y. R. Wong· 5 shared J. Zheng· 4 shared A. Odle· 3 shared A. Fehr· 2 shared D. Meyerholz· 2 shared K. Li· 2 shared M. E. Ortiz Bezara· 2 shared N. C. Wu· 2 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

L. Y. R. Wong

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Functional and antigenic characterization of SARS-CoV-2 spike fusion peptide by deep mutational scanning

R. Lei, E. Qing, A. Odle, M. Yuan, T. J. C. Tan, N. So, W. O. Ouyang, I. A. Wilson, T. Gallagher, S. Perlman, N. C. Wu, L. Y. R. Wong

This study uses deep mutational scanning to analyze the SARS-CoV-2 spike fusion peptide, identifying mutations affecting viral entry and antibody resistance.

bioRxiv · Nov 28, 2023Microbiology

Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike

T. J. C. Tan, A. Odle, R. Lei, K. A. Matreyek, S. Perlman, L.-Y. R. Wong, N. C. Wu

This study identifies S2 domain mutations in SARS-CoV-2 spike that reduce binding to antibodies, showing antigenic drift in this region and its impact on vaccine efficacy.

bioRxiv · Sep 27, 2023Microbiology

MERS-CoV endoribonuclease and accessory proteins jointly evade host innate immunity during infection of lung and nasal epithelial cells

C. Comar, C. Otter, J. Pfannenstiel, E. Doerger, D. Renner, L. H. Tan, S. Perlman, N. Cohen, A. Fehr, S. R. Weiss

This study shows that MERS-CoV's EndoU and accessory proteins NS4a/NS4b together suppress innate immunity, enabling viral replication, unlike SARS-CoV-2 which activates these pathways.

bioRxiv · Dec 20, 2021 · PreprintMicrobiology

Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YMA30 strain of SARS-CoV-2

K. V. Kibler, M. Szczerba, D. F. Lake, A. J. Roeder, M. Rahman, B. G. Hogue, L. Y. R. Wong, S. Perlman, Y. Li, B. L. Jacobs

bioRxiv · Dec 6, 2021Microbiology

Effective interferon (IFN)-lambda treatment regimen to control lethal MERS-CoV infection in mice

R. Dijkman, M. Selvaraj, H. H. Gad, S. More, R. Hartmann, S. Perlman, V. Thiel, R. Channappanavar

This study identifies an effective two-dose IFN-lambda regimen that protects mice from lethal MERS-CoV infection by reducing viral load and inflammation.

bioRxiv · May 26, 2021 · PreprintImmunology

Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19

S. Perlman, L. Y. R. Wong, J. Zheng, K. Wilhelmsen, K. Li, M. E. Ortiz Bezara, N. J. Schnicker, A. A. A. Pezzulo, P. J. Szachowicz, K. Klumpp, F. Aswad, J. Rebo, S. Narumiya, M. Murakami, D. Meyerholz, , P. B. McCray

This study identifies the PLA2G2D-PGD2/DP1 pathway as a therapeutic target for severe COVID-19 in middle-aged mice, showing protection through DP1 antagonism.

bioRxiv · Apr 20, 2021 · PreprintMicrobiology

Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection

C. Dampalla, J. Zheng, K. Perera, L. Y. R. Wong, D. Meyerholz, H. Nguyen, M. Kashipathy, K. Battaile, S. Lovell, Y. Kim, S. Perlman, W. Groutas, K.-O. Chang

This study shows that post-infection treatment with a deuterated protease inhibitor improves survival and reduces viral load in mice infected with SARS-CoV-2.

bioRxiv · Feb 5, 2021Microbiology

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

G. Ye, J. Gallant, C. Massey, K. Shi, W. Tai, J. Zheng, A. Odle, M. Vickers, J. Shang, Y. Wan, A. Drelich, K. Kempaiah, V. Tat, S. Perlman, L. Du, , F. Li

This paper develops a potent, low-cost nanobody therapeutic, Nanosota-1C-Fc, that effectively blocks SARS-CoV-2 infection in vitro and in vivo with high affinity and stability.

bioRxiv · Nov 17, 2020Microbiology

K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia

S. Perlman, J. Zheng, L. Y. R. WONG, K. Li, A. K. Verma, M. E. Ortiz Bezara, C. Wohlford-Lenane, M. R. Leidinger, M. C. Kundson, D. K. Meyerholz, P. B. McCray

This study uses K18-hACE2 mice to demonstrate severe SARS-CoV-2 infection in lungs and brains, thrombosis in severe cases, and the protective effect of convalescent plasma against lethal disease, while showing anosmia occurs independently of clinical outcome.

bioRxiv · Aug 7, 2020Microbiology

β-Coronaviruses use lysosomal organelles for cellular egress.

N. Altan-Bonnet, G. Y. Altan-Bonnet, S. Ghosh, T. Dellibovi-Ragheb, E. Pak, Q. Qiu, M. Fisher, P. Takvorian, C. Bleck, V. Hsu, A. Fehr, S. Perlman, M. Straus, G. Whittaker, C. A. de Haan

This study shows β-coronaviruses exit cells via lysosomal trafficking, not the secretory pathway, and identifies Arl8b as a regulator of this process.

bioRxiv · Jul 25, 2020 · PreprintMicrobiology

Coronavirus infection and PARP expression dysregulate the NAD Metabolome: an actionable component of innate immunity

C. D. Heer, D. J. Sanderson, L. S. Voth, Y. M. O. Alhammad, M. S. Schmidt, S. A. J. Trammell, S. Perlman, M. S. Cohen, A. R. Fehr, C. Brenner

This study shows that SARS-CoV-2 infection upregulates MARylating PARPs and NAD synthesis enzymes, and that enhancing NAD levels can reduce viral replication.

bioRxiv · Apr 17, 2020Microbiology